All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @the_endolls on TikTok · 876s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @the_endolls's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00If you are a woman who takes peptides or if you are a woman who is curious about taking
  2. 0:04peptides and you suffer with endometriosis, PCOS, uterine fibroids, or any type of inflammatory
  3. 0:10hormonal condition, I want to share what I think is the most powerful stack to help manage
  4. 0:16symptoms of those conditions as somebody who suffers with those conditions and has tried
  5. 0:20everything under the sun over the past decade to try and help those conditions including multiple
  6. 0:25surgical procedures. So let me share this in hopes that I can maybe help another woman out there.
  7. 0:29And the ones I want to talk about today are KPV, SS-31, and Terzepa Tide.
  8. 0:35I wanted to respond to this peptide video because there are some interesting mechanisms here
  9. 0:41that I would like to discuss but there's also some extremely concerning ones as well.
  10. 0:45You see when we're talking about it, endometriosis, PCOS, fibroids, fertility, inflammation,
  11. 0:51insulin resistance, mitochondria, and peptides in general, as was mentioned in the previous video,
  12. 0:57we can't afford to be casual because the question is not, can this make me feel better?
  13. 1:02The question you should be asking is this changing the disease environment for the better?
  14. 1:07Or is it giving me superficial relief while potentially feeding endometriosis, pushing it
  15. 1:14towards growth long term? You see, that's the real concern there.
  16. 1:19Let's start with a forensic look at Terzepa Tide. Terzepa Tide is a dual GIP and GLP1
  17. 1:24receptor agonist. That means it affects and crete in signaling, glucose control, insulin response,
  18. 1:29appetite regulation, metabolic inflammation, and often body weight.
  19. 1:33Now in PCOS, this makes a lot of sense. Many PCOS phenotypes are heavily tied to insulin resistance.
  20. 1:39So if a GLP1 drug improves insulin sensitivity, lowers blood glucose instability, lowers adipose-driven inflammation,
  21. 1:45helps restore ovulation and improves metabolic signaling.
  22. 1:48Then yes, in that context, it can be extremely helpful,
  23. 1:51especially in women with PCOS, insulin resistance, obesity related inflammation, or metabolic syndrome.
  24. 1:58That part is legitimate. But here's where the problem starts.
  25. 2:02She is now taking that logic and applying it directly to endometriosis by saying,
  26. 2:06endometriosis is driven by insulin resistance. And that is too broad.
  27. 2:10Endometriosis is not primarily an insulin resistance disease.
  28. 2:13Endometriosis is a complex disease involving local estrogen production,
  29. 2:18progesterone resistance, immune evasion, chronic inflammation, neuroangiogenesis,
  30. 2:24fibrosis, oxidative stress, pain sensitization, metabolic adaptation,
  31. 2:30and genetic and epigenetic dysregulation. So yes, torsopotide may help some women with endometriosis,
  32. 2:36but likely the women it helps most are those with a specific phenotype, for example.
  33. 2:41Endometriosis plus PCOS. Endometriosis plus insulin resistance.
  34. 2:46Endometriosis plus obesity-driven inflammation. Endometriosis plus blood sugar instability.
  35. 2:51Endometriosis plus metabolic dysfunction. For that group,
  36. 2:55GLP1 therapy may reduce systemic pressure on the disease environment.
  37. 2:58But that does not automatically make GLP1 drugs in endometriosis treatment.
  38. 3:02It makes them a metabolic tool that may indirectly improve symptoms in the right phenotype.
  39. 3:07So here's the most dangerous part that all of these peptide gurus don't seem to know.
  40. 3:11GLP1 receptor signaling is not universally anti-growth.
  41. 3:14In some disease models, GLP1 signaling appears anti-inflammatory and anti-proliferative.
  42. 3:20But in other receptor positive cellular contexts,
  43. 3:23GLP1 activation has been associated with increased growth signaling.
  44. 3:27So the question becomes, what tissue are we talking about?
  45. 3:31What receptor expression is present? What mutation background exists?
  46. 3:35What downstream pathway is being activated? Is it affecting PI3K, AKT?
  47. 3:39Is it affecting M-TOR? Is it affecting ERK?
  48. 3:42Is it changing insulin signaling? Is it changing nutrient sensing?
  49. 3:45It is not cancer, but endometriosis shares cancer-like behavior.
  50. 3:49It behaves in ways that overlap with tumor-like biology.
  51. 3:52It survives where it shouldn't. It invades tissue. It recruits blood vessels.
  52. 3:56It resists apoptosis. It remodels the extracellular matrix. It adapts metabolically.
  53. 4:01So if a drug can influence growth, nutrient sensing, insulin, survival signaling,
  54. 4:06and receptor-mediated cellular behavior, we cannot just assume it is neutral in every endometriosis phenotype.
  55. 4:12That would be lazy. Now, to be very clear, I'm not saying GLP1 drugs definitely fuel all cases of endometriosis.
  56. 4:20That would also be too broad. What I'm saying is this.
  57. 4:23GLP1 drugs are context-dependent, and there's very little research behind them.
  58. 4:28They may help one phenotype tremendously, and may not be appropriate for another.
  59. 4:33A woman with endo, PCOS, insulin resistance, and high systemic inflammation may respond beautifully.
  60. 4:39But a lean woman with endometriosis, no insulin resistance, strong ER-beta activity,
  61. 4:46angiogenic lesions, high PI3K, AKT signaling, and metabolically adaptive disease.
  62. 4:52Well, this is the exact mechanisms we see where GLP1 pushes growth.
  63. 4:57This is a completely different biological context.
  64. 5:00So before we start calling GLP1 drugs an endometriosis breakthrough, we need to ask,
  65. 5:05are we improving the woman's metabolic health, or are we also altering signals that the lesion could use for survival?
  66. 5:12That is the level of thinking this disease requires.
  67. 5:15Now, let's talk about KPV. Honestly, I haven't decided where I stand with this one.
  68. 5:19KPV is a small three amino acid peptide, lysine, proline, valine.
  69. 5:24It comes from the C-terminal region of alpha-malanocytes stimulating hormone, or alpha-MSH.
  70. 5:30And alpha-MSH biology is interesting because it plays a role in immune regulation and inflammation control.
  71. 5:37KPV has been studied for anti-inflammatory effects, especially in gut and epithelial barrier models.
  72. 5:43It may help regulate inflammatory signaling. It may support barrier function.
  73. 5:48It may have antimicrobial activity in certain experimental settings.
  74. 5:52So could KPV help some endometriosis patients? Possibly.
  75. 5:56Especially women with a phenotype involving gut inflammation, IBS-like symptoms, bloating, barrier irritation,
  76. 6:03immune overactivation, skin inflammation, histamine type reactivity, systemic inflammatory flares.
  77. 6:09That is a phenotype where KPV makes mechanistic sense.
  78. 6:12But here's where the claim goes too far.
  79. 6:14Calling KPV an off-switch for inflammation is not accurate.
  80. 6:18The immune system does not have one off-switch, and an endometriosis that matters.
  81. 6:23Because inflammation in endometriosis participates in lesion survival, tissue remodeling, angiogenesis, nerve sensitization,
  82. 6:31immune evasion, pain signaling, fibrosis.
  83. 6:34So if KPV reduces certain inflammatory signals, it may feel incredible.
  84. 6:38Less bloating, less cramping, less gut irritation, less inflammatory noise.
  85. 6:44But symptom relief does not automatically equal disease correction.
  86. 6:47Because if the lesion is still running, aromatase, ER beta dominance, progesterone resistance, VEGF signaling, MMP tissue invasion, platelet activation,
  87. 6:58macrophage polarization, neuroangiogenesis, then calming some inflammation may reduce the fire alarm without fixing the faulty wiring.
  88. 7:08That does not mean KPV is bad.
  89. 7:10It means it is not a complete model.
  90. 7:12It is a tool.
  91. 7:13And tools depend on phenotype.
  92. 7:15Now let's talk about SS-31.
  93. 7:17SS-31, also known as Alami pre-tied, is a mitochondria targeting peptide.
  94. 7:23It is designed to stabilize the inner mitochondrial membrane, especially through interactions with cardiolipin.
  95. 7:29The goal is to improve mitochondrial function, support ATP production, reduce oxidative stress, and improve cellular energy dynamics.
  96. 7:37On paper, that sounds amazing, especially because endometriosis is heavily tied to oxidative stress.
  97. 7:43Reactive oxygen species matter, mitochondrial dysfunction matters, iron driven oxidative damage matters, inflammatory macrophage activity matters, fatigue matters, cellular energy collapse matters.
  98. 7:56The reason some women feel good with SS-31 is typically due to their phenotype involving severe fatigue, mitochondrial dysfunction, post-inflammatory crashes, oxidative stress, long COVID overlap, low cellular energy.
  99. 8:10But here's where I truly want to caution the viewer.
  100. 8:13Endometriotic lesions are not simply weak, damaged tissue that need mitochondrial support.
  101. 8:18They are metabolically abnormal tissue.
  102. 8:20They adapt, they survive stress, they tolerate hypoxia.
  103. 8:24They resist apoptosis.
  104. 8:26And they can switch between metabolic programs depending on what the environment gives them.
  105. 8:30This is where people oversimplify mitochondrial support.
  106. 8:33They say, endometriosis has mitochondrial dysfunction.
  107. 8:37SS-31 supports mitochondria.
  108. 8:39Therefore, SS-31 helps endometriosis.
  109. 8:42That is too simple, because endometriosis cells are not just low energy.
  110. 8:47They are metabolically rewired.
  111. 8:49They can lean into glycolysis.
  112. 8:51They can lean into oxidative phosphorylation.
  113. 8:54They can shift through hypoxia signaling.
  114. 8:56They can use inflammatory signals.
  115. 8:58They can use estrogen signaling.
  116. 8:59They can use biosynthetic pathways.
  117. 9:01And one of the pathways we need to talk about is the pentose phosphate pathway, or PPP.
  118. 9:07Because when cells are proliferating, glucose is not just used to make ATP.
  119. 9:11Glucose can be diverted into the pentose phosphate pathway to produce everything the lesion needs to grow even further, like NADPH.
  120. 9:19Ribose 5 phosphate, reducing power, and building blocks for DNA, RNA, and lipids.
  121. 9:26So if a lesion is already in a survival and growth program, and you improve cellular energy capacity without correcting the mechanisms that control the metabolic switch,
  122. 9:36you may not be forcing the lesion toward death.
  123. 9:38You may be improving its ability to adapt.
  124. 9:41That is the concern.
  125. 9:42Now again, I'm not saying SS-31 definitely fuels endometriosis.
  126. 9:47That would be dishonest.
  127. 9:48What I'm saying is, if you do not target this correctly, if you do not address the machinery that lets endometriotic cells shift between glycolysis,
  128. 9:58oxidative phosphorylation, PPP, and survival metabolism, then mitochondrial support could theoretically help the host, but also help the lesion tolerate stress.
  129. 10:08That is the nuance.
  130. 10:09Endometriosis cells are not metabolically stupid.
  131. 10:12They are flexible.
  132. 10:13They can adapt between oxidative phosphorylation and glycolysis as needed.
  133. 10:17So if you support mitochondrial function, but do not address things like HIF-1 alpha, PDK-1, PDH suppression,
  134. 10:24PI3K, AKT, M-TOR, ER beta signaling, NFKB, COX-2, PGE-2, Aromatase, Oxidative Stress Tolerance, Immune Evasion.
  135. 10:36Then you may be improving energy while boosting the disease's control system, and that can be a problem long term.
  136. 10:42So the real question with SS-31 is not, does it reduce oxidative stress?
  137. 10:47The question is, which cells are benefiting from that reduced oxidative stress?
  138. 10:52Healthy cells, immune cells, nerve cells, or endometriotic cells too.
  139. 10:58Because if the woman feels more energy, less fatigue, and less inflammation, that matters.
  140. 11:04But if the lesion environment remains angiogenic, estrogenic, invasive, and metabolically adaptive, then we still have not solved the disease.
  141. 11:12We have improved the terrain around the woman.
  142. 11:14But we may not have corrected the lesion's survival program.
  143. 11:18That distinction matters.
  144. 11:20And you see this is my biggest issue with the peptide conversation.
  145. 11:24She may genuinely feel better.
  146. 11:28The women may genuinely feel better, and I'm not here to invalidate that.
  147. 11:34Relief does matter, and quality of life matters.
  148. 11:37But the feeling does not automatically prove the disease modification.
  149. 11:40That's kind of the trap.
  150. 11:42Your pain goes down, bloating improves, energy improves, and we assume the disease is handled.
  151. 11:47But if you actually look at the long-term comments of people taking peptides with an endometriosis, you see that's not at all what's going on.
  152. 11:55And the endometriosis is a disease environment.
  153. 11:58It's local estrogen production, progesterone resistance, immune innovation, mastil activation.
  154. 12:05The list continues.
  155. 12:06It's very complex.
  156. 12:07It's a network disease.
  157. 12:09And that's kind of the problem.
  158. 12:12If a compound can improve symptoms, but it leaves a deeper machinery active, while it may be useful temporarily, it's not the full answer.
  159. 12:21And here's my honest take.
  160. 12:24Pectites in general to include things like GOP one.
  161. 12:29I'm not going to really say that they are good for women with endometriosis.
  162. 12:34There's too little of data.
  163. 12:37If you were to go down that route, GOP one should be done under the care of a medical professional.
  164. 12:46That means blood work.
  165. 12:47That means imaging.
  166. 12:48KPV.
  167. 12:49I haven't really made up my mind on because just it's looks good.
  168. 12:56But there's also small little parts that I like to look deeper into.
  169. 13:01As a 31, I completely would be.
  170. 13:03Leery of specific to people with endometriosis because unless you know for a fact, you don't carry the same genetic mutations as those that we see in cancer, you could be literally lighting a fire.
  171. 13:18So this goes beyond is the Santee inflammatory does this improve myochondria to improve insulin.
  172. 13:26Sensitivity, the real question that you should be asking is what pathways that are affecting what tissue, what phenotype, what disease stage, what is the context.
  173. 13:38And that's the conversation you deserve to have not hype, not have tight worship like I've been seen, but actual systems biology because simply matriosis is now one disease pattern is multiple phenotypes hunting, hiding under a diagnosis.
  174. 13:55That's why you have someone with heavy fibrosis and no pain and someone with one lesion and severe chronic pain.
  175. 14:02There is a spectrum that no one seems to talk about or know or generally understand.
  176. 14:09And that's why certain things work for some and for some, they can send them into a crazy, crazy flare and grow.
  177. 14:17We shouldn't pretend that we can't help.
  178. 14:21There are absolutely good solutions out there.
  179. 14:24But you must also understand that unless you fully comprehend this at a deeper level, you may think that you're helping another woman, but the reality is you're helping their lesions.

GLP-1 peptides for endometriosis: hype vs. actual evidence

ENDOLLS

TikTok creator

2.4K viewsWatch on TikTok →

Quick answer

Tirzepatide (Mounjaro/Zepbound) is FDA-approved for type 2 diabetes and obesity, not for endometriosis or adenomyosis. Its potential indirect benefits for women with endometriosis likely apply specifically to those with concurrent insulin resistance, PCOS, or obesity-driven systemic inflammation, not to the broader endometriosis population. KPV and SS-31 remain experimental research peptides with no clinical trial evidence in gynecologic inflammatory disease.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For GLP-1 peptides for endometriosis: hype vs. actual evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

GLP-1 peptides for endometriosis: hype vs. actual evidence is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Start the provider review

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "GLP-1 peptides for endometriosis: hype vs. actual evidence" from ENDOLLS. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Mounjaro/Zepbound) is FDA-approved for type 2 diabetes and obesity, not for endometriosis or adenomyosis.

The reason this review is not generic is the source wording and the canonical claim label "glp1 peptides for endometriosis and adenomyosis do they work stit." In this clip, the useful excerpt is: "If you are a woman who takes peptides or if you are a woman who is curious about taking peptides and you suffer with endometriosis, PCOS, uterine fibroids, or any type of inflammatory hormonal condition, I want to share what I think is the..." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

GLP-1 drugs are most likely to benefit women with endometriosis who also have insulin resistance, PCOS, or obesity-related inflammation, not the broader endometriosis population.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide (Mounjaro/Zepbound) is FDA-approved for type 2 diabetes and obesity, not for endometriosis or adenomyosis.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide (Mounjaro/Zepbound) is FDA-approved for type 2 diabetes and obesity, not for endometriosis or adenomyosis. Its potential indirect benefits for women with endometriosis likely apply specifically to those with concurrent insulin resistance, PCOS, or obesity-driven systemic inflammation, not to the broader endometriosis population. KPV and SS-31 remain experimental research peptides with no clinical trial evidence in gynecologic inflammatory disease.
  • No clinical trials have tested tirzepatide, semaglutide, or any GLP-1 drug as a treatment for endometriosis specifically. Current evidence is mechanistic and observational.
  • GLP-1 drugs are most likely to benefit women with endometriosis who also have insulin resistance, PCOS, or obesity-related inflammation, not the broader endometriosis population.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • No clinical trials have tested tirzepatide, semaglutide, or any GLP-1 drug as a treatment for endometriosis specifically. Current evidence is mechanistic and observational.
  • GLP-1 drugs are most likely to benefit women with endometriosis who also have insulin resistance, PCOS, or obesity-related inflammation, not the broader endometriosis population.
  • A 2022 meta-analysis by Elkind-Hirsch et al. (Fertility and Sterility) confirmed GLP-1 receptor agonists improve metabolic and ovulatory outcomes in PCOS, supporting the PCOS-overlap argument made in this video.
  • KPV and SS-31 are unregulated research peptides. Neither has been studied in randomized clinical trials for endometriosis, adenomyosis, or any gynecologic condition.
  • The creator's concern about GLP-1 growth signaling in endometriosis tissue is speculative. No published study has shown tirzepatide or semaglutide promotes endometriosis lesion growth in humans.
  • Endometriosis affects roughly 10% of reproductive-age women globally and remains significantly undertreated. Self-prescribing a peptide stack is not a substitute for evaluation by a board-certified reproductive endocrinologist or endometriosis specialist.
  • Tirzepatide is a prescription drug approved for type 2 diabetes and obesity. Using it off-label for endometriosis should only occur under physician supervision with documented metabolic indications.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @the_endolls actually say?

The creator, who identifies as someone living with endometriosis and adenomyosis, made a case for a specific peptide "stack" including tirzepatide, KPV, and SS-31. The core argument was nuanced: tirzepatide may help some women with endometriosis, but only those with overlapping metabolic dysfunction. More provocatively, she warned that "GLP-1 receptor signaling is not universally anti-growth" and that in certain disease contexts, GLP-1 activation could theoretically push growth-promoting pathways, specifically PI3K, AKT, and mTOR, in endometriosis lesions that share "cancer-like behavior." She was careful to say she is not claiming GLP-1 drugs definitely fuel endometriosis, but that assuming they are neutral in every phenotype would be "lazy."

Does the science back this up?

On the metabolic overlap between PCOS and endometriosis, yes, largely. On the GLP-1 growth signaling concern in endometriosis tissue specifically, the evidence is thin, speculative, and extrapolated from unrelated disease models. That does not automatically make her wrong, but it does mean she is presenting hypothesis as near-established risk.

The PCOS-insulin-GLP-1 connection is well documented. A 2022 meta-analysis by Elkind-Hirsch et al. in Fertility and Sterility confirmed GLP-1 receptor agonists improve ovulation rates and metabolic markers in women with PCOS and insulin resistance. That part of her argument is solid ground.

Her claim that endometriosis is not "primarily an insulin resistance disease" is accurate. A 2021 review by Falconer et al. in Human Reproduction Update describes endometriosis as driven by local estrogen synthesis, progesterone resistance, immune dysregulation, and neuroangiogenesis, not primarily glucose metabolism.

The GLP-1 growth signaling concern is where the evidence gets murky. Studies showing GLP-1 receptor activation stimulating PI3K-AKT pathways come mostly from pancreatic beta-cell and certain cancer cell line research, not endometriosis tissue. Applying that logic to endo lesions is an extrapolation, a reasonable one to flag, but an extrapolation nonetheless.

What did they get wrong (or right)?

She got a lot right, and deserves credit for it. Most peptide content on TikTok skips phenotype entirely. The fact that she separated PCOS-dominant endometriosis from lean, non-insulin-resistant endometriosis is clinically meaningful and reflects real heterogeneity in the literature.

Where she overcooks it: the framing of GLP-1 drugs potentially "feeding endometriosis" is stated with a confidence level that outpaces the evidence. There is currently no published clinical data showing tirzepatide or semaglutide promotes endometriosis lesion growth in humans. The mechanistic concern she raises, GLP-1 receptor expression in endometrial stromal cells activating proliferative signaling, has not been specifically studied in endometriosis tissue in peer-reviewed literature as of early 2025.

She also promotes KPV and SS-31 as part of a "stack" without acknowledging that neither peptide has any published clinical trial evidence in endometriosis or adenomyosis. SS-31 (elamipretide) has early-stage mitochondrial research, mostly in cardiac and renal tissue. KPV has preclinical anti-inflammatory data in gut models. Presenting these alongside tirzepatide as a coherent treatment strategy for endo is not supported by evidence.

What should you actually know?

GLP-1 drugs are not endometriosis treatments. They are metabolic drugs with documented benefits in insulin resistance, PCOS, and obesity-related inflammation. If you have endometriosis and also have insulin resistance, PCOS, or significant metabolic dysfunction, a GLP-1 agonist might reduce systemic inflammatory burden. That is a plausible, indirect benefit, not a disease-modifying treatment for endometriosis itself.

The phenotype argument she makes is genuinely useful. A lean woman with no metabolic dysfunction, high estrogen-driven lesion activity, and no PCOS overlap is not the same patient as someone with endo, PCOS, and insulin resistance. Treating them identically is bad medicine. On that point, she is ahead of most TikTok health creators.

What is missing entirely: there is no mention of consulting a reproductive endocrinologist or endometriosis specialist before adding any of these compounds. Tirzepatide is a prescription medication. KPV and SS-31 are unregulated research peptides not approved by the FDA for any indication. None of these should be self-prescribed based on a social media video, regardless of how medically literate that video sounds.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

ENDOLLS · TikTok creator

2.4K views on this video

Peptides for endometriosis and adenomyosis, do they work? #stitch with @sam #endometriosis #adenomyosis #endolls #womenshealth

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about no clinical trials have tested tirzepatide, semaglutide,?

No clinical trials have tested tirzepatide, semaglutide, or any GLP-1 drug as a treatment for endometriosis specifically. Current evidence is mechanistic and observational.

What does the video say about glp-1 drugs?

GLP-1 drugs are most likely to benefit women with endometriosis who also have insulin resistance, PCOS, or obesity-related inflammation, not the broader endometriosis population.

What does the video say about a 2022 meta-analysis by elkind-hirsch et al. (fertility?

A 2022 meta-analysis by Elkind-Hirsch et al. (Fertility and Sterility) confirmed GLP-1 receptor agonists improve metabolic and ovulatory outcomes in PCOS, supporting the PCOS-overlap argument made in this video.

What does the video say about kpv?

KPV and SS-31 are unregulated research peptides. Neither has been studied in randomized clinical trials for endometriosis, adenomyosis, or any gynecologic condition.

What does the video say about the creator's concern about glp-1 growth signaling in endometriosis tissue?

The creator's concern about GLP-1 growth signaling in endometriosis tissue is speculative. No published study has shown tirzepatide or semaglutide promotes endometriosis lesion growth in humans.

What does the video say about endometriosis affects roughly 10% of reproductive-age women globally?

Endometriosis affects roughly 10% of reproductive-age women globally and remains significantly undertreated. Self-prescribing a peptide stack is not a substitute for evaluation by a board-certified reproductive endocrinologist or endometriosis specialist.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ENDOLLS, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.